Diagnostic Imaging in Renal Evaluation
Solstice Pharmaceuticals B.V. is involved in clinical research centered on ultrasound contrast agents used for kidney imaging, with a focus on assessing indeterminate renal lesions through enhanced diagnostic visualization.
- Ultrasound contrast agent development
- Kidney lesion characterization
- Renal imaging quality
The sponsor’s research activity is directed toward improving the clinical utility of contrast-enhanced ultrasound in nephrology and radiology.
Contrast Microbubble Safety and Tolerability
Its clinical trial portfolio includes investigation of microbubble-based contrast agents in healthy subjects, with attention to safety and tolerability following intravenous administration.
- Microbubble contrast agent assessment
- Intravenous contrast exposure
- Human safety evaluation
This area reflects a therapeutic interest in diagnostic agents designed to support non-invasive imaging while maintaining a favorable clinical safety profile.
Kidney Ultrasound Imaging Performance
Research activity also addresses the imaging behavior of contrast-enhanced ultrasound in the kidney, with emphasis on image quality relevant to clinical interpretation and lesion assessment.
- Renal ultrasound visualization
- Imaging performance
- Diagnostic clarity
The sponsor’s focus includes the practical use of contrast media for improving visibility of renal structures during diagnostic examination.
